TABLE 1.
Case | Group | Age (y) | Sex | Clinical diagnosis or cause of death | Postmortem delay (h) | Braak NFT stage | Thal Aβ phase | Tissue usage |
1 | Youth | 12 | F | Thalassemia | 12 | N/A* | N/A | IHC** |
2 | Youth | 14 | M | Leukemia | 9 | N/A | N/A | IHC/WB** |
3 | Youth | 14 | F | Tuberculosis | 10 | N/A | N/A | IHC |
4 | Youth | 16 | F | Transposition of the great arteries | 8 | N/A | N/A | IHC |
5 | Youth | 19 | M | Infection/sepsis | 11 | N/A | N/A | IHC/WB** |
6 | Youth | 19 | M | Cardiopulmonary failure | 5 | N/A | N/A | IHC/WB** |
7 | Youth | 22 | F | Lupus erythematosus | 12 | N/A | N/A | IHC/WB** |
8 | Adult | 31 | F | Vagina cancer | 10 | 0 | 0 | IHC |
9 | Adult | 38 | M | Liver cancer | 8 | 0 | 0 | IHC/WB** |
10 | Adult | 49 | M | Lung cancer | 10 | 0 | 0 | IHC/WB** |
11 | Adult | 50 | M | Lung cancer | 7 | 0 | 0 | IHC/IF/WB** |
12 | Adult | 50 | F | Myocardial infarction | 12 | 0 | 0 | IHC/WB** |
13 | Adult | 55 | M | Liver cancer | 8 | 0 | 0 | IHC**/IF |
14 | Aged | 68 | M | Renal failure | 8 | II | 0 | IHC/WB** |
15 | Aged | 70 | F | Pneumonia | 12 | II | 0 | IHC |
16 | Aged/AD*** | 74 | M | Multisystem failure, demented | 5 | V | 5 | IHC** |
17 | Aged | 76 | M | Heart stroke | 7 | 0 | 0 | IHC/IF |
18 | Aged | 77 | M | Multisystem failure | 12 | III | 0 | IHC/WB** |
19 | Aged | 80 | M | Iron-deficiency anemia | 7 | III | 0 | IHC/WB** |
20 | Aged | 80 | M | Lung cancer | 15 | III | 1 | IHC |
21 | Aged | 81 | F | Chronic renal failure | 7 | IV | 0 | IHC** |
22 | Aged | 81 | M | Cardiovascular failure | 6 | II | 0 | IHC/WB** |
23 | Aged/AD | 83 | F | Multisystem failure, demented | 12 | III | 4 | IHC/WB** |
24 | Aged/AD | 85 | M | Astrocytoma, demented | 12 | III | 4 | IHC** |
25 | Aged | 86 | M | COPD**** | 6 | III | 0 | IHC/WB** |
26 | Aged/AD | 87 | F | Coronary heart disease, demented | 6 | VI | 5 | IHC/WB** |
27 | Aged/AD | 88 | F | Heart failure, demented | 9 | V | 4 | IHC/WB** |
28 | Aged | 95 | M | Multisystem failure | 14 | III | 0 | IHC |
*AD-type neuropathology not assessed; **Used for assessing regional and age-related change in Shank3 expression; ***Cases met the criteria for neuropathological diagnosis of AD (Braak and Braak, 1991; Thal et al., 2002; Braak et al., 2006; Montine et al., 2012); ****chronic obstructive pulmonary disease.
IHC, immunohistochemistry; IF, immunofluorescence; WB, western blot.